... and here is a link to the just-announced results of the multiple-ascending-dose (MAD) trial:
Clinical Results Presented from Prothena's Phase 1b Study of PRX2/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson's Disease (NASDAQ:PRTA)
Quick summary:
- the Phase 1 trials were successful;
- a global Phase 2 trial of approximately 300 patients with early PD is planned to commence in the second quarter of 2017.